US12622891B2 - AMP-activated protein kinase activator - Google Patents
AMP-activated protein kinase activatorInfo
- Publication number
- US12622891B2 US12622891B2 US18/566,730 US202218566730A US12622891B2 US 12622891 B2 US12622891 B2 US 12622891B2 US 202218566730 A US202218566730 A US 202218566730A US 12622891 B2 US12622891 B2 US 12622891B2
- Authority
- US
- United States
- Prior art keywords
- compound
- group
- mmol
- mixture
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active, expires
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/34—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021-094481 | 2021-06-04 | ||
| JP2021094481 | 2021-06-04 | ||
| PCT/JP2022/023390 WO2022255499A1 (ja) | 2021-06-04 | 2022-06-03 | 新規なamp活性化プロテインキナーゼ活性化剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| US20240277657A1 US20240277657A1 (en) | 2024-08-22 |
| US12622891B2 true US12622891B2 (en) | 2026-05-12 |
Family
ID=84322602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US18/566,730 Active 2043-06-09 US12622891B2 (en) | 2021-06-04 | 2022-06-03 | AMP-activated protein kinase activator |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US12622891B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4349331A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JPWO2022255499A1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN117794527A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022255499A1 (cg-RX-API-DMAC7.html) |
Citations (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040162317A1 (en) | 2003-02-06 | 2004-08-19 | Georg Fertig | Mono-acylated o-phenylendiamines derivatives |
| US20050090529A1 (en) | 2003-07-31 | 2005-04-28 | Pfizer Inc | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
| WO2006062224A1 (ja) | 2004-12-07 | 2006-06-15 | Takeda Pharmaceutical Company Limited | カルボキサミド誘導体 |
| WO2006088921A2 (en) | 2005-02-16 | 2006-08-24 | Schering Corporation | Pyrazinyl substituted piperazine-piperidines with cxcr3 antagonist activity |
| US20070037888A1 (en) | 2003-10-17 | 2007-02-15 | Astrazeneca Ab | 4-(Pyrazol-3-ylamino) pyrimidine derivatives for use in the treatment of cancer |
| JP2008504285A (ja) | 2004-06-23 | 2008-02-14 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | ガン化学療法薬として有用な2−アミノアリールカルボキシアミド |
| JP2011178728A (ja) | 2010-03-02 | 2011-09-15 | Kobe Univ | Ampk活性化剤、glut4活性化剤、およびそれらを用いた医薬品・飲食品 |
| WO2011162267A1 (ja) | 2010-06-22 | 2011-12-29 | 株式会社 三和化学研究所 | 新規チオフェンカルボキサミド誘導体及びその医薬用途 |
| US20130345243A1 (en) | 2011-03-07 | 2013-12-26 | Glaxosmithkline Llc | 1h-pyrollo[3,2-d]pyrimidinedione derivatives |
| WO2014069426A1 (ja) | 2012-10-31 | 2014-05-08 | 塩野義製薬株式会社 | Ampk活性化作用を有するベンズイミダゾールおよびアザベンズイミダゾール誘導体 |
| WO2014204895A1 (en) | 2013-06-18 | 2014-12-24 | Albert Einstein College Of Medicine Of Yeshiva University | Treatment of obesity and pulmonary arterial hypertension |
| WO2018174078A1 (ja) | 2017-03-21 | 2018-09-27 | 富士フイルム株式会社 | ペプチド化合物およびその製造方法、スクリーニング用組成物、並びにペプチド化合物の選択方法 |
| JP2020083811A (ja) | 2018-11-22 | 2020-06-04 | 国立大学法人 鹿児島大学 | 1,5−アンヒドロフルクトース誘導体を含むampk活性化剤 |
| US20200339742A1 (en) * | 2019-04-29 | 2020-10-29 | The Government Of The United States Of America, As Represented By The Secretary Of The Navy | Breathable Elastomeric Composites with Tether-Containing Conducting Polymers for Nanoscale Diffusion Control and Protection |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004043366A2 (en) | 2002-11-06 | 2004-05-27 | Smithkline Beecham Corporation | Sulfonamides |
| JP7131034B2 (ja) | 2018-03-30 | 2022-09-06 | 株式会社三洋物産 | 遊技機 |
-
2022
- 2022-06-03 JP JP2023525939A patent/JPWO2022255499A1/ja active Pending
- 2022-06-03 EP EP22816244.2A patent/EP4349331A4/en active Pending
- 2022-06-03 CN CN202280053568.2A patent/CN117794527A/zh active Pending
- 2022-06-03 WO PCT/JP2022/023390 patent/WO2022255499A1/ja not_active Ceased
- 2022-06-03 US US18/566,730 patent/US12622891B2/en active Active
Patent Citations (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7501451B2 (en) | 2003-02-06 | 2009-03-10 | Hoffmann-La Roche Inc. | Mono-acylated o-phenylendiamines derivatives |
| US20060089403A1 (en) | 2003-02-06 | 2006-04-27 | Georg Fertig | Mono-acylated o-phenylendiamines derivatives |
| US7071219B2 (en) | 2003-02-06 | 2006-07-04 | Hoffmann-La Roche Inc. | Mono-acylated o-phenylendiamines derivatives |
| JP2006516553A (ja) | 2003-02-06 | 2006-07-06 | エフ.ホフマン−ラ ロシュ アーゲー | 新規なモノ−アシル化o−フェニレンジアミン誘導体 |
| US20040162317A1 (en) | 2003-02-06 | 2004-08-19 | Georg Fertig | Mono-acylated o-phenylendiamines derivatives |
| US20050090529A1 (en) | 2003-07-31 | 2005-04-28 | Pfizer Inc | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
| US20070037888A1 (en) | 2003-10-17 | 2007-02-15 | Astrazeneca Ab | 4-(Pyrazol-3-ylamino) pyrimidine derivatives for use in the treatment of cancer |
| US7579349B2 (en) | 2003-10-17 | 2009-08-25 | Astrazeneca Ab | 4-(pyrazol-3-ylamino) pyrimidine derivatives for use in the treatment of cancer |
| JP2007510626A (ja) | 2003-10-17 | 2007-04-26 | アストラゼネカ アクチボラグ | 癌の治療に使用の4−(ピラゾール−3−イルアミノ)ピリミジン誘導体 |
| JP2008504285A (ja) | 2004-06-23 | 2008-02-14 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | ガン化学療法薬として有用な2−アミノアリールカルボキシアミド |
| US20080293696A1 (en) | 2004-06-23 | 2008-11-27 | Bayer Pharmaceuticals Corporation | 2-Aminoarylcarboxamides Useful as Cancer Chemotherapeutic Agents |
| WO2006062224A1 (ja) | 2004-12-07 | 2006-06-15 | Takeda Pharmaceutical Company Limited | カルボキサミド誘導体 |
| US7868005B2 (en) | 2005-02-16 | 2011-01-11 | Schering Corporation | Pyrazinyl substituted piperazine-piperidines with CXCR3 antagonist activity |
| US20070054919A1 (en) | 2005-02-16 | 2007-03-08 | Schering Corporation | Pyrazinyl substituted piperazine-piperidines with CXCR3 antagonist activity |
| WO2006088921A2 (en) | 2005-02-16 | 2006-08-24 | Schering Corporation | Pyrazinyl substituted piperazine-piperidines with cxcr3 antagonist activity |
| JP2011178728A (ja) | 2010-03-02 | 2011-09-15 | Kobe Univ | Ampk活性化剤、glut4活性化剤、およびそれらを用いた医薬品・飲食品 |
| WO2011162267A1 (ja) | 2010-06-22 | 2011-12-29 | 株式会社 三和化学研究所 | 新規チオフェンカルボキサミド誘導体及びその医薬用途 |
| US20130345243A1 (en) | 2011-03-07 | 2013-12-26 | Glaxosmithkline Llc | 1h-pyrollo[3,2-d]pyrimidinedione derivatives |
| JP2014507453A (ja) | 2011-03-07 | 2014-03-27 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 1H−ピロロ[3,2−d]ピリミジンジオン誘導体 |
| WO2014069426A1 (ja) | 2012-10-31 | 2014-05-08 | 塩野義製薬株式会社 | Ampk活性化作用を有するベンズイミダゾールおよびアザベンズイミダゾール誘導体 |
| WO2014204895A1 (en) | 2013-06-18 | 2014-12-24 | Albert Einstein College Of Medicine Of Yeshiva University | Treatment of obesity and pulmonary arterial hypertension |
| US20160113933A1 (en) | 2013-06-18 | 2016-04-28 | Albert Einstein College Of Medicine, Inc. | Treatment of obesity and pulmonary arterial hypertension |
| US9603852B2 (en) | 2013-06-18 | 2017-03-28 | Albert Einstein College Of Medicine, Inc. | Treatment of obesity and pulmonary arterial hypertension |
| WO2018174078A1 (ja) | 2017-03-21 | 2018-09-27 | 富士フイルム株式会社 | ペプチド化合物およびその製造方法、スクリーニング用組成物、並びにペプチド化合物の選択方法 |
| US20200040039A1 (en) | 2017-03-21 | 2020-02-06 | Fujifilm Corporation | Peptide compound and method for producing same, composition for screening use, and method for selecting peptide compound |
| US11319347B2 (en) | 2017-03-21 | 2022-05-03 | Fujifilm Corporation | Peptide compound and method for producing same, composition for screening use, and method for selecting peptide compound |
| JP2020083811A (ja) | 2018-11-22 | 2020-06-04 | 国立大学法人 鹿児島大学 | 1,5−アンヒドロフルクトース誘導体を含むampk活性化剤 |
| US20200339742A1 (en) * | 2019-04-29 | 2020-10-29 | The Government Of The United States Of America, As Represented By The Secretary Of The Navy | Breathable Elastomeric Composites with Tether-Containing Conducting Polymers for Nanoscale Diffusion Control and Protection |
Non-Patent Citations (16)
| Title |
|---|
| Extended European Search Report dated May 14, 2025 in European Patent Application No. 22816244.2. |
| International Application No. PCT/JP2022/023390, International Preliminary Report on Patentability, mailed May 29, 2023. |
| Kim et al., AMPK activators: mechanisms of action and physiological activities, Experim. Mol. Med., 48:e224 (2016). |
| Martin et al., An Elastomeric Poly(Thiophene-EDOT) Composite with a Dynamically Variable Permeability Towards Organic and Water Vapors, Adv. Func. Mat., 22(15):3116-3127 (2012). |
| Motoshima et al., AMPK and cell proliferation—AMPK as a therapeutic target for atherosclerosis and cancer, J. Physiol., 574(Pt 1):63-71 (2006). |
| O'Neiii, AMPK and Exercise: Glucose Uptake and Insulin Sensitivity, Diab. Metab. J., 7(1):1-21 (2013). |
| Pilkington-Miksa, et al., "Design, synthesis, and biological evaluation of novel cRGD-Paclitaxel conjugates for integrin-assisted drug delivery", Bioconjugate Chemistry, vol. 23, No. 8, pp. 1610-1622 (2012). |
| Ruderman et al., AMPK, insulin resistance, and the metabolic syndrome, J. Clin. Invest., 123(7):2764-2772 (2013). |
| Extended European Search Report dated May 14, 2025 in European Patent Application No. 22816244.2. |
| International Application No. PCT/JP2022/023390, International Preliminary Report on Patentability, mailed May 29, 2023. |
| Kim et al., AMPK activators: mechanisms of action and physiological activities, Experim. Mol. Med., 48:e224 (2016). |
| Martin et al., An Elastomeric Poly(Thiophene-EDOT) Composite with a Dynamically Variable Permeability Towards Organic and Water Vapors, Adv. Func. Mat., 22(15):3116-3127 (2012). |
| Motoshima et al., AMPK and cell proliferation—AMPK as a therapeutic target for atherosclerosis and cancer, J. Physiol., 574(Pt 1):63-71 (2006). |
| O'Neiii, AMPK and Exercise: Glucose Uptake and Insulin Sensitivity, Diab. Metab. J., 7(1):1-21 (2013). |
| Pilkington-Miksa, et al., "Design, synthesis, and biological evaluation of novel cRGD-Paclitaxel conjugates for integrin-assisted drug delivery", Bioconjugate Chemistry, vol. 23, No. 8, pp. 1610-1622 (2012). |
| Ruderman et al., AMPK, insulin resistance, and the metabolic syndrome, J. Clin. Invest., 123(7):2764-2772 (2013). |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4349331A4 (en) | 2025-06-11 |
| JPWO2022255499A1 (cg-RX-API-DMAC7.html) | 2022-12-08 |
| WO2022255499A1 (ja) | 2022-12-08 |
| CN117794527A (zh) | 2024-03-29 |
| EP4349331A1 (en) | 2024-04-10 |
| US20240277657A1 (en) | 2024-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2981114T3 (es) | 8-ciano-5-piperidino-quinolinas como antagonistas de TLR7/8 y sus usos para el tratamiento de trastornos inmunitarios | |
| CN112707900B (zh) | 蛋白降解剂及其在疾病治疗中的应用 | |
| RU2667060C2 (ru) | Производные маннозы для лечения бактериальных инфекций | |
| JP6174117B2 (ja) | 抗炎症活性でコンジュゲートされた増強された抗インフルエンザ剤 | |
| ES2732311T3 (es) | Compuestos de manósidos y procedimientos de uso de los mismos | |
| US20220169628A1 (en) | Therapeutic agents and methods of treatment | |
| EP1813614B1 (en) | Cytotoxic agents comprising new tomaymycin derivatives | |
| KR20210107046A (ko) | 거대고리 화합물 및 질환 치료에서 이들의 용도 | |
| US20110166128A1 (en) | Diaryldiazepine Prodrugs for the Treatment of Neurological and Psychological Disorders | |
| US20110166194A1 (en) | Asenapine Prodrugs | |
| KR101837488B1 (ko) | 광학적으로 순수한 벤질-4-클로로페닐-c-글루코사이드 유도체 | |
| EA021196B1 (ru) | Ингибиторы вирусов flaviviridae | |
| US12552757B2 (en) | NRF2-activating compound | |
| AU2014248717B2 (en) | Mannose derivatives for treating bacterial infections | |
| US10072006B2 (en) | Heterocyclic compounds and their use in preventing or treating bacterial infections | |
| US20250195475A1 (en) | Cdk2 inhibitor and preparation method and use thereof | |
| JP2022521453A (ja) | 複素環式の誘導体 | |
| US20250179055A1 (en) | Substituted 2-(pyrrolidine-3-yl)acetic acid derivative, preparation method and use thereof | |
| CA3100333A1 (en) | Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway | |
| CA2946833A1 (en) | Pyrrolopyrimidine compounds for prevention of tumors based on nae inhibitory effect | |
| CN108403698A (zh) | 用于治疗细菌感染的方法和组合物 | |
| US20240277657A1 (en) | Novel amp-activated protein kinase activator | |
| CN112118891B (zh) | 作为流感病毒复制抑制剂的稠和多环吡啶酮化合物 | |
| US20180086760A1 (en) | Heterocyclic compounds and their use in preventing or treating bacterial infections | |
| CN112533917B (zh) | 作为vps34的抑制剂的吗啉衍生物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
| FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
| AS | Assignment |
Owner name: KYOTO PHARMACEUTICAL UNIVERSITY, JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:NAKATA, SUSUMU;KOJIMA, NAOTO;SIGNING DATES FROM 20231220 TO 20231222;REEL/FRAME:066275/0793 |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION Free format text: ALLOWED -- NOTICE OF ALLOWANCE NOT YET MAILED |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: ALLOWED -- NOTICE OF ALLOWANCE NOT YET MAILED |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT RECEIVED Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED |
|
| STCF | Information on status: patent grant |
Free format text: PATENTED CASE |